TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01765348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Syntax treatment via sentence-combining method
Description: Sentence combining method is a discrete trial method that teaches children to form complex sentences of a same structure through drilling and modeling.~Treatments are conduced by school-speech therapist once two weeks for 8 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Syntax treatment managed by narrative-based treatment
Description: Target structures are embedded into narrative stories. Children are exposed to these stories and are scaffolded to form the target sentence structure through answering questions, cloze passage and story retell. Treatment are conduced by school-speech therapist once two weeks for 8 sessions.
Study: NCT03550872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Participants will perform physical training three times a week on a stationary bicycle. The exercise intensity will be controlled between 14 and 16 by the Borg Scale for 40 minutes
Study: NCT00356356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg/wk administered as 2-25 mg SQ injections at separate injection sites
Study: NCT03630458

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White rice
Description: White rice was tested as a comparator for gastric emptying rate, glycemic response, fermentability, and appetitive response.
Study: NCT02967328

Intervention type: OTHER
Intervention: RP% Measurement by FCM as a Diagnostic Test for ITP
Study: NCT01867710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg twice daily
Description: type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg once daily
Description: type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken once daily, in the morning after a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 2.5 mg twice daily
Description: type = exact number; unit = mg; number = 2.5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg once daily
Description: type = exact number; unit = mg; number = 0.5; form = tablet; route = oral; taken once daily, in the morning after breakfast
Study: NCT02362672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-181 BID tablets
Description: NKTR-181 tablets 100-400 mg twice daily (BID)
Study: NCT02860858

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreous aflibercept injection
Study: NCT02362672

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match NKTR-181 BID tablets
Description: Placebo to match NKTR-181 tablets 100-400 mg twice daily (BID)
Study: NCT05397392

Intervention type: OTHER
Intervention: guideline recommended routine treatment

Intervention type: OTHER
Intervention: guideline recommended routine treatment
Study: NCT01651520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET with 11C-Flumazenil
Description: PET with 11C-Flumazenil.

Intervention type: DRUG
Group type: OTHER
Intervention: PET with 11C-Flumazenil
Description: PET with 11C-Flumazenil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET with 11C-Flumazenil
Description: PET with 11C-Flumazenil.
Study: NCT02093117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver
Description: continuous positive airway pressure of 30 cm of water for 30 seconds

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham recruitment maneuver
Description: Continuous positive airway pressure of 5 cm of water for 30 seconds
Study: NCT00624481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide Nasal Spray
Description: teriparatide intranasally daily for 24 weeks
Study: NCT04010240

Intervention type: OTHER
Intervention: Retrospective cohort
Description: Tumor material tested positive will be analyzed by next-generation sequencing to identify NTRK1, NTRK2 or NTRK3 gene fusions.
Study: NCT02950870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir-Paritaprevir-Ritonavir
Description: The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: The patient will be treated daily with Dasubavir 500 mg total dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Patients will be treated with ribavirin if necessary.
Study: NCT01645358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helmet (Starmed)
Description: The helmet is a kind of interface similar to a hood to deliver NIV

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Face mask (Respironics)
Description: The total face mask is the classical interface for NIV delivery
Study: NCT02091479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFH Early group
Description: Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily).
Study: NCT02637076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem
Description: single 3.0 gram dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem
Description: single 3.0 gram dose
Study: NCT04979234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina- Endoscopic Sleeve Gastroplasty
Description: Endoscopic gastric reduction
Study: NCT02091479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFH Late group
Description: Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily).
Study: NCT02736227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Withdrawal and Everolimus Monotherapy
Description: During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.
Study: NCT04147754

Intervention type: PROCEDURE
Intervention: Epidural anesthesia
Description: Preoperative epidural anesthesia at physician discretion
Study: NCT01651520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET with 11C-Flumazenil
Description: PET with 11C-Flumazenil.
Study: NCT02135185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: custom work endurance
Description: Experimental: Rehabilitation effort

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary management adapted to the nutritional status
Description: dietary management adapted to the nutritional status
Study: NCT04147754

Intervention type: PROCEDURE
Intervention: Intrathecal morphine
Description: Preoperative intrathecal morphine at physician discretion

Intervention type: PROCEDURE
Intervention: Erector spinae block
Description: Preoperative erector spinae block at physician discretion
Study: NCT02863445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-based emergency contraception 1.5 mg
Description: Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-based emergency contraception 3.0mg
Description: Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
Study: NCT02410525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PF-06427878
Description: Single administration via intravenous infusion of 20 ug \[11C\]PF-06427878 on Day 1 of all 3 Periods
Study: NCT04979234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Multidisciplinary follow up
Study: NCT01486277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quisinostat, 12 mg
Description: Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
Study: NCT02341599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6183
Description: MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6183
Description: MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6183
Description: MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6183
Description: MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6183
Description: MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.
Study: NCT00119795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Increase Physical Activity to 150 min/wk

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Lose 7-10% of body weight and increase physical activity to 150 min/wk

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: Lectures on information relevant to successful aging
Study: NCT04230993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sea water solution
Description: Administration of different sea water solution is performed and the rating of cold symptoms according to the Jackson scale, the fluidity of mucus and the ease of blowing will be evaluated.
Study: NCT03359070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapaconazole
Description: Application of 1 gram on the lesion.
Study: NCT04230993

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sea water solution
Description: Administration of different sea water solution is performed and the rating of cold symptoms according to the Jackson scale, the fluidity of mucus and the ease of blowing will be evaluated.
Study: NCT01105078

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flow rate
Description: Different flow rate during cardiopulmonary bypass
Study: NCT03404947

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: For one exercise session, participants will be asked to ingest a quantity of ethanol (in the form of vodka) sufficient to maximally stimulate liver alcohol metabolism.
Study: NCT01515865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine HCl
Description: dose at subject's current dose level
Study: NCT03359070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconazole Nitrate
Description: Application of 1 gram on the lesion.
Study: NCT04539574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7 Tesla Magnetic Resonance Imaging
Description: Undergo 7T MRI
Study: NCT01515865

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose of matching placebo
Study: NCT03636971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid with mannitol
Description: single shot injection (Ostenil Plus®, TRB Chemedica SA, CH, 1800kD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid with sorbitol
Description: single shot injection (Synolis®, Gebro-Pharma AG, CH, 2000 kD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: single shot injection of saline, same volume
Study: NCT02410525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878 10 mg
Description: Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878 600 mg
Description: Single oral administration of 600 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
Study: NCT04539574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00929084

Intervention type: OTHER
Group type: OTHER
Intervention: The Survivor Stories Tablet
Description: The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.

Intervention type: OTHER
Group type: OTHER
Intervention: The Survivor Stories Tablet
Description: The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
Study: NCT04309045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT
Description: Today, the most well-known and established treatment for borderline personality disorder is Dialectical Behavior Therapy (DBT) that developed by Marsha Linhan in the 1990s. DBT is currently used in other disorders such as: eating disorders, addictions, impulse control problems and bipolar disorder. Various studies have found a beneficial effect for this treatment in various areas: decreased suicidal thoughts and attempts and self-harm behaviors, improvements in suicide attempts, anger levels, impulsive behaviors, depressive symptoms, The use of drugs, the percentage of dropouts from treatment, number Hospitalization and general function.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DDP
Description: DDP treatment is part of a trend of dynamic therapies to treat borderline personality disorder. The DDP focuses on deficiencies in the emotional experience processing and is performed in the form of weekly, individual sessions with a trained therapist over a 12-18 month period. Treatment is based on the need to correct three neurocognitive functions responsible for adaptive processing of emotional experiences: association (the ability to recognize, understand their existence, and experience a sequence of emotional experiences), attribution (the ability to make complex attributions about the self and others), and the ability to make realistic attribution, about the self and the other. Interventions that activate these three functions are the basis for DDP treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Patients on the waiting list for treatment, or patients in the hospital under routine care.
Study: NCT02658630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot + TTT exercise
Description: The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
Study: NCT03013023

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BS
Description: NNS, FT, positional support, and oral sucrose feeding

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: Routine NICU care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PITP
Description: Parents will learn to regulate infant responses while implementing caregiving activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BS+PITP
Description: Parents will learn to regulate infant responses while implementing caregiving activities. Supportive interventions, i.e., NNS, FT, positional support, and oral sucrose feeding, will be provided while infants are undergoing painful procedures.
Study: NCT03439592

Intervention type: DIAGNOSTIC_TEST
Intervention: collection of fecal material
Description: in study population we will collect fecal material to analyze the microbiotic flora by genetic techniques.

Intervention type: DIAGNOSTIC_TEST
Intervention: collection of fecal material
Description: in study population we will collect fecal material to analyze the microbiotic flora by genetic techniques.
Study: NCT04015635

Intervention type: OTHER
Intervention: None involved
Description: NO intervention

Intervention type: OTHER
Intervention: None involved
Description: NO intervention
Study: NCT03124316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticipated regret
Description: Induce awareness of future regret about the unwanted behaviour

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticipated regret
Description: Induce awareness of future regret about the unwanted behaviour

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticipated regret
Description: Induce awareness of future regret about the unwanted behaviour

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticipated regret
Description: Induce awareness of future regret about the unwanted behaviour

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Material incentive
Description: Inform that valued objects will be delivered if and only if that has been progress in performing the desired behaviours

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Material incentive
Description: Inform that valued objects will be delivered if and only if that has been progress in performing the desired behaviours

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Material incentive
Description: Inform that valued objects will be delivered if and only if that has been progress in performing the desired behaviours

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Material incentive
Description: Inform that valued objects will be delivered if and only if that has been progress in performing the desired behaviours

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving
Description: Analyze or prompt the person to factors that influence the behaviour and select strategies that help overcome barriers
Study: NCT05226520

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental probiotic product
Description: Probiotic supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo
Study: NCT04279639

Intervention type: BEHAVIORAL
Intervention: qigong
Description: Patients of the Pain Management Unit either experience usual treatment, or usual treatment plus qigong practice.